Mitsubishi Tanabe Pharma Canada has announced that RADICAVA IV (edaravone) will be discontinued for use in Canada, and the distribution of the therapy will end as early as April 1, 2025. This decision was made as part of the transition process to RADICAVA Oral Suspension and is not related to any safety concerns.
Eligible patients can continue to access RADICAVA Oral Suspension, a liquid formulation of the therapy taken either orally or through a feeding tube, which was approved by Health Canada in November 2022 and is available in all provinces and territories through their public formularies.
We encourage people living with ALS and their families to consult with their clinicians for guidance during this transition.